Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
=== Respiratory effects === The most severe side effect associated with buprenorphine is respiratory depression (insufficient breathing). It occurs more often in those who are also taking benzodiazepines or alcohol, or have underlying lung disease. The usual reversal agents for opioids, such as naloxone, may be only partially effective, and additional efforts to support breathing may be required. Respiratory depression may be less than with other opioids, particularly with chronic use. In the setting of acute pain management, though, buprenorphine appears to cause the same rate of respiratory depression as other opioids such as morphine. Central sleep apnea is possible with long-term use, possibly resolving with dose reduction.
== Pharmacokinetics == The volume of distribution of avalglucosidase alfa was 3.4 L in patients who had Pompe disease of a late onset. The average half-life of avalglucosidase alfa was 1.6 hours, measured in patients with late stage Pompe disease. There is little information available on the metabolism of the avalglucosidase alfa. The protein portion of the drug however does break down into small peptides via catabolic pathways. The clearance of the drug is 0.9 L/hour in patients that exhibited late-stage Pompe disease.
At the beginning of the North African campaign, Brigadier General Lyman L. Lemnitzer accompanied Major General Mark Wayne Clark by submarine to North Africa. Upon arrival, about 60 officers were awarded the Legion of Merit and were among the first awarded the medal. By some misunderstanding as to the rules governing the awards, these 60 American officers were awarded the degree of Officer. According to Lemnitzer, President Roosevelt was quite annoyed but did not rescind the awards. These were the only U.S. officers (or service personnel of any rank) awarded the Legion of Merit with a degree. In 1943 Willem Jan Kruys received the Legion of Merit (Officer) in Australia as captain of the Dutch destroyer HMNS Tjerk Hiddes for the three rescue trips to Timor in December 1942 during which 1100 people were saved from the beaches of Timor under Japanese occupation. The certificate was signed by President Roosevelt personally. In 1960 Kruys received the Legion of Merit again when retired as vice-admiral of the Royal Dutch Navy, this time with gold star and combat V. In March 1945, Colonel Hsieh Mang, of the Chinese Army was awarded the Legion of Merit for his work with the First American Volunteer Group "Flying Tigers". In 1945, Lieutenant Colonel William E. Fairbairn, a former British General Service Corps who transferred to United States as "officer in rent" to train SOE agents and later the Office of Strategic Services (OSS), for his achievements in training OSS personnel. Fairbairn eventually rose to the rank of lieutenant-colonel by the end of the war, and received the U.S.
Sources: en.wikipedia.org
Ownership of the shroud passed from the House of Savoy to the Catholic Church after the death of the former king Umberto II of Italy in 1983. The microscopist and forensic expert Walter McCrone found, based on his examination of samples taken in 1978 from the surface of the shroud using adhesive tape, that the image on the shroud had been painted with a dilute solution of red ochre pigment in a gelatin medium. McCrone also found that the apparent bloodstains were painted with vermilion pigment, also in a gelatin medium. McCrone's findings were disputed by other researchers, and the nature of the image on the shroud continues to be debated. In 1988, radiocarbon dating by three independent laboratories established that the shroud dates back to the Middle Ages, between 1260 and 1390. The nature and history of the shroud have been the subjects of extensive and long-lasting controversies in both the scholarly literature and the popular press. Although the radiocarbon dating of the shroud is accepted as valid by experts, it continues to generate significant public debate. Defenders of the authenticity of the shroud have questioned the radiocarbon results, usually on the basis that the samples tested might have been contaminated or taken from a repair to the original fabric. Such fringe theories, which have been rejected by most experts, include the medieval repair theory, the bio-contamination theories and the carbon monoxide theory. Currently, the Catholic Church neither endorses nor rejects the authenticity of the shroud as a relic of Jesus.
Female cultivars include 'Liberty Splendor', 'Santa Cruz', and 'Golden Girl', the latter so named because of the striking yellow color of its leaves in the fall; all female cultivars release zero pollen. Many cultivars are listed in the literature in the UK, of which the compact 'Troll' has gained the Royal Horticultural Society's Award of Garden Merit. Ginkgos adapt well to the urban environment, tolerating pollution and confined soil spaces. They rarely have disease problems, even in urban conditions, and are attacked by few insects. Ginkgos are popular subjects for growing as miniature landscapes known as penjing and bonsai; they can be kept artificially small and tended over centuries. The trees are easy to propagate from seed.
=== Phosphoenolpyruvate carboxykinase (PEPC-K) === Glyceroneogenesis can be regulated at two reaction pathways. First, it can be held at the decarboxylation of oxaloacetate to phosphoenolpyruvate. Secondly, the TCA cycle can affect glyceroneogenesis when the glutamate or substrates in the TCA cycle are being used as a precursor. Decarboxylation of oxaloacetate to phosphoenolpyruvate is catalyzed by PEPC-K, the essential enzyme which regulates glyceroneogenesis. Increases in PEPC-K levels or overexpression of the gene that codes for PEPC-K will increase glyceroneogenesis. Also, oxaloacetate can be decarboxylated to phosphoenolpyruvate when more PEPC-K can catalyze the reaction. Gene expression of PEPC-K can be suppressed by norepinephrine, glucocorticoids, and insulin. Norepinephrine is a neurotransmitter which decreases the activity of PEPC-K when the cell is in a cold environment. Glucocorticoids are steroid hormones involved in the reciprocal regulation of glyceroneogenesis in the liver and adipose tissues. Through a poorly-understood mechanism, they induce transcription of PEPC-K in the liver while decreasing transcription in adipose tissues. Insulin is a peptide hormone that causes cells to take in glucose. Through glyceroneogenesis, insulin down-regulates the expression of PEPC-K in both liver and adipose tissues.
The traditions of British centenarians receiving greetings and congratulations was established by King Edward VII in 1908. The famous acrobat and tightrope walker Henry Johnson received a congratulatory letter from Edward VII via his royal courtier Viscount Knollys in 1906. The tradition of royal congratulations continued in 1908, when the secretary for King Edward VII sent a congratulatory letter to Reverend Thomas Lord of Horncastle, Lincolnshire, in a newspaper clipping, declaring, "I am commanded by the King to congratulate you on the attainment of your hundredth year, after a most useful life." The practice was formalised from 1917, under the reign of King George V, who also sent congratulations then sent by a telegram on the attainment of a diamond wedding anniversary (or jubilee) marking 60 years of marriage. During the reign of King George V, only 24 telegrams were sent; however, with the aging population, this increased to 273 during 1952, when Queen Elizabeth II ascended the throne. The Queen also sent a telegram, and later a portrait-style greeting card with the notation, "I am so pleased to know that you are celebrating your one hundredth birthday. I send my congratulations and best wishes to you on such a special occasion." Each few years the card was updated with a current updated picture of the Queen to ensure people did not receive the same card more than once. The Queen further sent her congratulations on one's 105th birthday and every year thereafter as well as on special wedding anniversaries.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.